CivilsWisdom.
Updated · Today
Economics March 20, 2026 4 min read Daily brief · #39 of 105

Production Linked Incentive Scheme

The Production Linked Incentive (PLI) scheme for Pharmaceuticals, approved by the Union Cabinet in February 2021, has attracted actual investment of Rs 27,45...

GS2 GS3

What Happened

  • The Production Linked Incentive (PLI) scheme for Pharmaceuticals, approved by the Union Cabinet in February 2021, has attracted actual investment of Rs 27,453 crore — exceeding the committed target of Rs 17,275 crore — as of December 2023.
  • The scheme selected 55 applicants from 278 applications received against a financial outlay of Rs 15,000 crore.
  • It covers three product categories: biopharmaceuticals and complex generics (Category 1); Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) (Category 2); and other drugs (Category 3).
  • The scheme aims to reduce India's dependence on imported APIs — particularly from China — and diversify domestic pharmaceutical production toward high-value goods.
  • 20 of the 55 selected participants are MSMEs, reflecting the scheme's inclusive design.

Static Topic Bridges

Production Linked Incentive (PLI) Scheme Architecture

The PLI scheme is a supply-side industrial policy instrument that provides financial incentives to manufacturers based on incremental sales above a pre-defined base year. Unlike capital subsidies, PLI is output-linked — firms earn incentives only when they produce and sell more. The pharmaceuticals PLI is one of 14 sectors covered under the umbrella PLI programme approved under the Atmanirbhar Bharat strategy.

  • Operational guidelines for pharma PLI were issued on June 1, 2021 by the Department of Pharmaceuticals.
  • Incentive rates vary by product category and year (typically 3–10% of incremental sales over 6 years).
  • Category 1 (complex/high-value products) carries higher incentive rates than Category 3 (commodity generics).
  • The 14 PLI sectors span mobile phones, medical devices, auto components, textiles, solar PV, specialty steel, food processing, and white goods among others.
  • Nodal ministry for pharma PLI: Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers.

Connection to this news: The investment overrun (₹27,453 crore actual vs ₹17,275 crore committed) signals that industry confidence in the pharma sector's growth potential is higher than anticipated — a vindication of PLI as a policy design.

India's API Dependence and Import Vulnerability

Active Pharmaceutical Ingredients (APIs) are the biologically active components in medicines. India, despite being the world's largest supplier of generic medicines (supplying ~20% of global generic volume), is heavily dependent on China for about 70% of its API and KSM requirements. This supply chain vulnerability became visible during the COVID-19 pandemic when Chinese exports were disrupted.

  • India supplies 60% of global vaccine demand, 40% of US generic drugs, and 25% of UK medicines.
  • Bulk drugs (APIs) are a subclause of pharmaceutical manufacturing; a separate PLI scheme for bulk drugs (Rs 6,940 crore) runs parallel to the general pharma PLI to specifically incentivise API production.
  • Key therapeutic areas for API import dependence: antibiotics (penicillin, amoxicillin), vitamins (B1, B12, C), and antipyretics (paracetamol).
  • The Pharma Park scheme (three parks approved) complements PLI by providing plug-and-play infrastructure for API manufacturing clusters.

Connection to this news: Category 2 of the pharma PLI directly targets the API and KSM gap, aiming to rebuild domestic supply chains that were exposed as strategically vulnerable during COVID-19.

Atmanirbhar Bharat and Industrial Policy

Atmanirbhar Bharat (Self-Reliant India) was announced in May 2020 as a Rs 20 lakh crore economic package combining immediate relief measures with long-term structural reforms. Its industrial policy dimension centred on PLI schemes across 14 sectors, aimed at raising India's global manufacturing competitiveness and reducing import dependence in strategic goods. This represented a notable revival of active industrial policy after decades of liberal orthodoxy.

  • Total PLI outlay across 14 sectors: approximately Rs 1.97 lakh crore over 5 years.
  • Target: Add Rs 30 lakh crore in production and create 60 lakh jobs over five years.
  • Other manufacturing enablers: National Logistics Policy (2022), PM Gati Shakti (infrastructure master plan), Industrial Corridors.
  • Concern raised: PLI tends to favour large established firms and may not adequately benefit small manufacturers or generate proportionate employment relative to capital deployed.

Connection to this news: The pharma PLI's over-achievement on investment — and its inclusion of 20 MSMEs — addresses both the Atmanirbhar Bharat strategic goal (reduce import vulnerability) and the equity goal (MSME participation).

Key Facts & Data

  • Scheme: PLI for Pharmaceuticals; approved by Union Cabinet: February 24, 2021
  • Nodal ministry: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
  • Financial outlay: Rs 15,000 crore (over 6 years)
  • Applicants received: 278; selected: 55 (including 20 MSMEs)
  • Committed investment: Rs 17,275 crore; actual investment realised: Rs 27,453 crore (Dec 2023)
  • Three product categories: Biopharmaceuticals/complex generics (Cat 1), APIs/KSMs (Cat 2), Other drugs (Cat 3)
  • India's pharma exports: ~$27 billion annually; world's largest generic medicines supplier
  • China API dependence: ~70% of India's API/KSM requirements
  • A parallel PLI scheme for bulk drugs (APIs only): Rs 6,940 crore approved separately
On this page
  1. What Happened
  2. Static Topic Bridges
  3. Production Linked Incentive (PLI) Scheme Architecture
  4. India's API Dependence and Import Vulnerability
  5. Atmanirbhar Bharat and Industrial Policy
  6. Key Facts & Data
Display